- BRAFTOVI -

A BREAKTHROUGH IN OVERALL SURVIVAL

From a Phase 3 trial in BRAFv600E-mutant mCRC

Image
Home page banner Braftovi


BRAFTOVI + CETUXIMAB

BRAFTOVI is indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, who have received prior systemic therapy.1

 

Image
Braftovi encorafenib

Presentation

BRAFTOVI (encorafenib) is a targeted therapy that demonstrates, in combination with cetuximab, a breakthrough in overall survival.1 BEACON CRC, the first Phase 3 trial to exclusively study patients with BRAFV600E-mutant mCRC, demonstrates unprecedented OS and ORR results for these patients.3

Based on BEACON CRC data, the European Commission approved BRAFTOVI for patients with BRAFV600E-mutant mCRC, who have received prior systemic therapy.1

BRAFTOVI regimen provides an actionable reason to test all patients with mCRC for a BRAFV600E  mutation at diagnosis.2

Image
our objectives

Choose BRAFTOVI + cetuximab for your patients with BRAFV600E-mutant mCRC, who have received prior systemic therapy


 

BRAFTOVI + cetuximab provide an actionable reason to test all patients with mCRC for BRAFV600E mutation at diagnosis2